AZD7798

Phase 2Small molecule

AstraZeneca

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Moderate to Severe Crohn's DiseaseActive, not recruiting

Moderate to Severe Crohn's DiseasePhase 2

Active, not recruiting

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Moderate to Severe Crohn's Disease

NCT06450197

Q3 2027

Phase 2Recruiting

Crohn's Disease

NCT06681324

Clinical

Trials by Indication[1]

Crohn's Disease4 trials

Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Patients With Crohn's Disease.

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT06432764·9 enrolled

Positron Emission Tomography (PET) Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT06053424·13 enrolled

AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's Disease

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT05452304·112 enrolled

Show 1 more trial

Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT06681324·30 enrolled

Moderate to Severe Crohn's Disease1 trial

A Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of AZD7798 in Patients With Moderate to Severe Crohn's Disease

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT06450197·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for AZD7798. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD7798 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD7798. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca